Abstract
μ-Opioid receptor desensitization is considered an initial step in the development of tolerance. Curiously, the commonly used opioid morphine produces robust tolerance but minimal acute desensitization. This study was designed to test the hypothesis that desensitization is indeed present in morphine-treated animals and is distinguished from cellular tolerance by time course of recovery and mechanism. To induce tolerance, rats were treated with continuously released morphine for 1 week. Morphine-mediated activation of G protein-coupled inwardly rectifying potassium conductance was measured using voltage-clamp recordings from locus ceruleus neurons in brain slices from naive or morphine-treated rats. Cellular tolerance was observed as a decrease in morphine efficacy in slices from morphine-treated rats. This tolerance persisted for at least 6 h. An additional reduction in morphine-mediated current was observed when slices from morphine-treated rats were continuously maintained in morphine at approximately the circulating plasma concentration. This additional reduction recovered within 1 h after removal of morphine from the slice and represents desensitization that developed in the tolerant animal. Recovery from desensitization, but not long-lasting tolerance, was facilitated by protein phosphatase 1 (PP1) activity. Furthermore, desensitization, but not tolerance, was reversed by protein kinase C (PKC) inhibitor but not by an inhibitor of c-Jun N-terminal kinase. Therefore, morphine treatment leads to both long-lasting cellular tolerance and readily reversible desensitization, which are differentially dependent on PP1 and PKC activity and combine to result in a substantial decrease in morphine effectiveness. This PKC-mediated desensitization may contribute to the previously reported PKC-dependent reversal of behavioral tolerance.
Footnotes
This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grants R01-DA08163, F32-DA33036]; and the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant T32-NS07381].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
ABBREVIATIONS:
- MOR
- μ-opioid receptor
- MTA
- morphine-treated animal
- LC
- locus coeruleus
- ME
- [Met5]-enkephalin
- DAMGO
- [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
- PKC
- protein kinase C
- PP1
- protein phosphatase 1
- JNK
- c-Jun N-terminal kinase
- MK-801
- dizocilpine maleate
- SP600125
- anthra[1–9-cd]pyrazol-6(2H)-one
- UK
- UK14304 tartrate, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine tartrate
- Gö6976
- 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile
- ACSF
- artificial cerebrospinal fluid
- ANOVA
- analysis of variance
- GIRK
- G protein-coupled inwardly rectifying potassium
- NA
- noradrenaline.
- Received July 25, 2012.
- Accepted August 22, 2012.
- Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|